-+ 0.00%
-+ 0.00%
-+ 0.00%

Luz Saúde launches SKYPS sarilumab trial in children with systemic juvenile idiopathic arthritis

PUBT·09/15/2026 08:34:53
Listen to the news
Luz Saúde launches SKYPS sarilumab trial in children with systemic juvenile idiopathic arthritis
  • Luz Saúde opened recruitment at Hospital da Luz Lisboa for the SKYPS clinical study in systemic juvenile idiopathic arthritis.
  • Results have not been presented; the study will generate safety and effectiveness data for sarilumab in children and youths.
  • Trial targets patients aged 1 to 17, aiming to address inconsistent responses to existing therapies in this rare inflammatory disease.
  • Program could support future treatment options in paediatric rheumatology if the drug shows a favorable benefit-risk profile.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Luz Saúde SA published the original content used to generate this news brief on September 15, 2026, and is solely responsible for the information contained therein.